S
KPTI icon

SignatureFD’s Karyopharm Therapeutics KPTI Stock Holding History

SignatureFD’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-40
Closed -$3K – 3354
2022
Q3 		$3K Buy
40
+27
+208% +$2.02K ﹤0.01% 2655
2022
Q2 		$1K Sell
13
-59
-82% -$5.41K ﹤0.01% 2943
2022
Q1 		$8K Sell
72
-46
-39% -$5.73K ﹤0.01% 2266
2021
Q4 		$11K Sell
118
-8
-6% -$797 ﹤0.01% 2087
2021
Q3 		$11K Buy
126
+23
+22% +$2.39K ﹤0.01% 2019
2021
Q2 		$16K Buy
103
+6
+6% +$871 ﹤0.01% 1809
2021
Q1 		$15K Buy
97
+24
+33% +$5.06K ﹤0.01% 1685
2020
Q4 		$17K Buy
73
+62
+564% +$14.4K ﹤0.01% 1515
2020
Q3 		$2K Sell
11
-8
-42% -$1.96K ﹤0.01% 2226
2020
Q2 		$5K Buy
19
+7
+58% +$2.07K ﹤0.01% 1809
2020
Q1 		$3K Sell
12
-5
-29% -$1.38K ﹤0.01% 1833
2019
Q4 		$5K Buy
+17
New +$3.69K ﹤0.01% 1637

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SignatureFD's KPTI Position: Q4 2022 in Review

SignatureFD sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 40 shares — an estimated $3K sold.

SignatureFD first reported a position in KPTI in Q4 2019 and held it in 12 quarters. The position peaked at $17K in Q4 2020. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • SignatureFD reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • SignatureFD sold 40 Karyopharm Therapeutics shares in Q4 2022, an estimated $3K.
  • SignatureFD first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 12 quarters.
  • SignatureFD's Karyopharm Therapeutics position peaked at $17K in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on SignatureFD's 13F filing for Q4 2022, filed 30 Jan 2023.